Advertisement

Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development

  • Elina Petrova
Chapter
Part of the International Series in Quantitative Marketing book series (ISQM, volume 20)

Abstract

Continuous innovation is one of the pharmaceutical industry’s most defining characteristics. New medications can be crucial for maintaining the quality of human life, and may even affect its duration. The sales potential is staggering: the global pharmaceutical market is expected to reach $1.1 trillion by 2015. The pressure to succeed is tremendous. Yet, pharmaceutical innovation is hardly an orderly, predictable process. It follows a technology-push model dependent on a meandering path of scientific breakthroughs with uneven timing and hard to foresee outcomes. Technological competency, decades of rigorous research, and profound understanding of unmet customer needs, while necessary, may prove insufficient for market success as the critical decision for commercialization remains outside the firm.

Drug innovation as a business process requires savvy strategic, organizational, and managerial decisions. It is already enjoying intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving drug discovery and development. In this chapter, we present a comprehensive overview of the process of drug innovation from a business and academic perspective. We discuss the evolving organizational forms and models for collaboration, summarize significant empirical regularities, and highlight differences in market positions related to firms’ strategic orientation, innovation emphasis, attitudes to risk, and specialized resources. As a guide to future research, critical drivers and modes for drug innovation are systematized in a unifying framework of characteristics and process decisions, and multiple areas in need of further scrutiny, analysis, and optimization are suggested. Because of its rich potential and high significance, research on drug innovation seems poised to gain increasing momentum in the years to come.

Keywords

Generic Drug Pharmaceutical Firm Therapeutic Category Pharmaceutical Innovation Market Exclusivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Acemoglu D, Linn J (2004) Market size in innovation: theory and evidence from the pharmaceutical industry. Quart J Econ 119(3):1049–1090CrossRefGoogle Scholar
  2. Angell M (2004) Excess in the pharmaceutical industry. Can Med Assoc J 171(12):1451–1453CrossRefGoogle Scholar
  3. Arora A, Gambardella A, Magazzini L, Pammolli F (2007) A breath of fresh air? Firm type, scale, scope and selection effects in drug development, working paperGoogle Scholar
  4. Bottazzi G, Dosi G, Lippi M, Pammolli F, Riccaboni M (2001) Innovation and corporate growth in the evolution of the drug industry. Int J Ind Organ 19:1161–1187CrossRefGoogle Scholar
  5. Cassiman B, Ueda M (2006) Optimal project rejection and new firm start-ups. Manag Sci 52(2):262–275CrossRefGoogle Scholar
  6. Chan T, Nickerson JA, Owan H (2007) Strategic management of R&D pipelines with co-specialized investments and technology markets. Manag Sci 53(4):667–682CrossRefGoogle Scholar
  7. Chandy R, Hopstaken B, Narasimhan O, Prabhu J (2006) From invention to innovation: conversion ability in product development. J Market Res XLIII:494–508CrossRefGoogle Scholar
  8. Cockburn IM (2007) Is the pharmaceutical industry in a productivity crisis? In: Lerner J, Stern S (eds) Innovation policy and the economy, vol 7. NBER, MIT Press, CambridgeGoogle Scholar
  9. Cockburn IM, Henderson RM (1996) Public-private interaction in pharmaceutical research. Proc Natl Acad Sci 93:12725–12730CrossRefGoogle Scholar
  10. Cockburn IM, Henderson RM (1998) Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. J Ind Econ 46(2):157–182CrossRefGoogle Scholar
  11. Cockburn IM, Henderson RM (2001a) Publicly funded science and the productivity of the pharmaceutical industry. In: Jaffe A, Lerner J, Stern S (eds) Innovation policy and the economy, vol 1. NBER, MIT Press, CambridgeGoogle Scholar
  12. Cockburn IM, Henderson RM (2001b) Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. J Health Econ 20:1033–1057CrossRefGoogle Scholar
  13. Cohen WM, Levintal DA (1989) Innovation and learning: the two faces of R&D. Econ J 99:569–596CrossRefGoogle Scholar
  14. Cohen WM, Levintal DA (1990) Absorptive capacity: a new perspective on learning and innovation. Adm Sci Q 35(1):128–152CrossRefGoogle Scholar
  15. Danzon PM, Nicholson S, Pereira NS (2005) Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. J Health Econ 24:317–339CrossRefGoogle Scholar
  16. Deeds DL, Hill CWL (1996) Strategic alliances and the rate of new product development: an empirical study of entrepreneurial biotechnology firms. J Bus Venturing 11:41–55CrossRefGoogle Scholar
  17. DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ 28:469–479CrossRefGoogle Scholar
  18. DiMasi JA, Paquette C (2004) The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics 22:1–14CrossRefGoogle Scholar
  19. DiMasi J, Grabowski HG, Vernon J (1995) R&D costs, innovative output and firm size in the pharmaceutical industry. Int J Econ Bus 2(2):201–219CrossRefGoogle Scholar
  20. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185CrossRefGoogle Scholar
  21. Ding M, Eliashberg J (2002) Structuring the new product development pipeline. Manag Sci 48(3):343–363CrossRefGoogle Scholar
  22. Ding M, Eliashberg J (2008) A dynamic competitive forecasting model incorporating dyadic decision making. Manag Sci 54(4):820–834CrossRefGoogle Scholar
  23. Gans JS, Stern S (2000) Incumbency and R&D incentives: licensing the gale of creative destruction. J Econ Manag Strat 9(4):485–511CrossRefGoogle Scholar
  24. Gassmann O, Reepmeyer G (2005) Organizing pharmaceutical innovation: from science-based knowledge creators to drug-oriented knowledge brokers. Creativity Innov Manag 14(3):233–245CrossRefGoogle Scholar
  25. Gassmann O, von Zedtwitz M (1998) Organization of industrial R&D on a global scale. R&D Manag 28(3):147–161CrossRefGoogle Scholar
  26. Gilbert J, Henske P, Singh A (2003), Rebuilding Big Pharma’s business model. In: In vivo: the business and medicine report, 21(10), www.elsevierbi.com
  27. Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. Int J Res Market 25:247–260CrossRefGoogle Scholar
  28. Grabowski H, Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 35(2):331–350CrossRefGoogle Scholar
  29. Grabowski H, Vernon J, DiMasi J (2002) Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20(3):11–29CrossRefGoogle Scholar
  30. Grewal R, Chakravarty A, Ding M, Liechty J (2008) Counting chickens before the eggs hatch: associating new product development portfolios with shareholder expectations in the pharmaceutical sector. Int J Res Market 25:261–272CrossRefGoogle Scholar
  31. Griliches Z, Cockburn I (1994) Generics and new goods in pharmaceutical price indexes. Am Econ Rev 84(5):1213–1232Google Scholar
  32. Hagedoorn J (1993) Understanding the rationale of strategic technology partnering: interorganizational modes of cooperation and sectoral differences. Strat Manag J 14:371–385CrossRefGoogle Scholar
  33. Hahn M, Park S, Krishnamurthi L, Zoltners AA (1994) Analysis of new product diffusion using a four-segment trial-repeat model. Market Sci 13(3):224–247CrossRefGoogle Scholar
  34. Henderson R, Cockburn I (1994) Measuring competence? Exploring firm effects in pharmaceutical research. Strat Manag J 15:63–84CrossRefGoogle Scholar
  35. Henderson R, Cockburn I (1996) Scale, scope and spillovers: the determinants of research productivity in drug discovery. Rand J Econ 27(1):32–59CrossRefGoogle Scholar
  36. Higgins MJ, Rodriguez D (2006) The outsourcing of R&D through acquisitions in the pharmaceutical industry. J Financ Econ 80:351–383CrossRefGoogle Scholar
  37. Hoang H, Rothaermel FT (2005) The effect of general and partner-specific alliance experience on joint R&D project performance. Acad Manag J 48(2):332–345CrossRefGoogle Scholar
  38. Hollis A (2002) The importance of being first: evidence from Canadian generic pharmaceuticals. Health Econ 11:723–734CrossRefGoogle Scholar
  39. Hollis A (2003) The anti-competitive effects of brand-controlled “Pseudo-generics in the Canadian pharmaceutical market”. Can Public Pol 29(1):21–32CrossRefGoogle Scholar
  40. Hollis A (2004) Me-too drugs: is there a problem? Mimeo, Department of Economics, University of Calgary, CalgaryGoogle Scholar
  41. Hudson J (2000) Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. Int Rev Law Econ 20:205–221CrossRefGoogle Scholar
  42. Kanavos P, Costa-Font J, Seeley E (2008) Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy 23:499–544CrossRefGoogle Scholar
  43. Khulji SE, Mroczkowski T, Bernstein B (2006) From invention to innovation: toward developing an integrated innovation model for biotech firms. J Prod Innov Manag 23:528–540CrossRefGoogle Scholar
  44. Lane PJ, Lubatkin M (1998) Relative absorptive capacity and interorganizational learning. Strat Manag J 19:461–477CrossRefGoogle Scholar
  45. Lee J (2003) Innovation and strategic divergence: an empirical study of the U.S. pharmaceutical industry from 1920 to 1960. Manag Sci 49(2):143–159CrossRefGoogle Scholar
  46. Magazzini L, Pammolli F, Riccaboni M (2004) Dynamic competition in pharmaceuticals. Eur J Health Econ 5:175–182CrossRefGoogle Scholar
  47. Morton FMS (1999) Entry decisions in the generic pharmaceutical industry. Rand J Econ 30(3):421–440CrossRefGoogle Scholar
  48. Morton FMS (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. Int J Ind Organ 18:1085–1104CrossRefGoogle Scholar
  49. Nerkar A, Roberts PW (2004) Technological and product-market experience and the success of new product introductions in the pharmaceutical industry. Strat Manag J 25:779–799CrossRefGoogle Scholar
  50. PhRMA (2011) Pharmaceutical Industry Profile 2011. PhRMA, Washington, DCGoogle Scholar
  51. Powell WW, Koput KW, Smith-Doerr L (1996) Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology. Adm Sci Q 41(1):116–145CrossRefGoogle Scholar
  52. Rao AG, Yamada M (1988) Forecasting with a repeat purchase model. Manag Sci 34(6):734–752CrossRefGoogle Scholar
  53. Rothaermel FT (2001a) Complementary assets, strategic alliances, and the incumbent’s advantage: an empirical study of industry and firm effects in the biopharmaceutical industry. Res Policy 30:1235–1251CrossRefGoogle Scholar
  54. Rothaermel FT (2001b) Incumbent’s advantage through exploiting complementary assets via interfirm cooperation. Strat Manag J 22(6/7):687–699CrossRefGoogle Scholar
  55. Rothaermel FT, Deeds DL (2006) Alliance type, alliance experience and alliance management capability in high-technology ventures. J Bus Venturing 21:419–460CrossRefGoogle Scholar
  56. Shan WJ, Walker G, Kogut B (1994) Interfirm cooperation and startup innovation in the biotechnology industry. Strat Manag J 15:387–394CrossRefGoogle Scholar
  57. Shankar V (1999) New product introduction and incumbent response strategies: their interrelationship and the role of multimarket contract. J Market Res 36:327–344CrossRefGoogle Scholar
  58. Shankar V (2008) Strategic marketing decision models for the pharmaceutical industry. In: Wierenga B (ed) Handbook of marketing decision models. Springer, New YorkGoogle Scholar
  59. Shankar V, Carpenter G, Krishnamurthi L (1998) Late mover advantage: how innovative late entrants outsell pioneers. J Market Res 35:54–70CrossRefGoogle Scholar
  60. Shankar V, Carpenter G, Krishnamurthi L (1999) The advantages of entry in the growth stage of the product life cycle: an empirical analysis. J Market Res 36:269–276CrossRefGoogle Scholar
  61. Simonet D (2002) Licensing agreements in the pharmaceutical industry. Int J Med Market 2(4):329–341CrossRefGoogle Scholar
  62. Sorescu AB, Chandy RK, Prabhu JC (2003) Sources and financial consequences of radical innovation. J Market 67:82–102CrossRefGoogle Scholar
  63. Stremersch S, van Dyck W (2009) Marketing of the life sciences: a new framework and research agenda for a nascent field. J Market 73(July):4–30CrossRefGoogle Scholar
  64. Stuart TE, Hoang H, Hybels RC (1999) Interorganizational endorsements and the performance of entrepreneurial ventures. Adm Sci Q 44:315–349CrossRefGoogle Scholar
  65. Thomke S, Kuemmerle W (2002) Asset accumulation, interdependence and technological change: evidence from pharmaceutical drug discovery. Strat Manag J 23(7):619–635CrossRefGoogle Scholar
  66. Vakratsas D, Kolsarici C (2008) A dual-market diffusion model for a new prescription pharmaceutical. Int J Res Market 25:282–293CrossRefGoogle Scholar
  67. Wuyts S, Dutta S (2008) Licensing exchange—insights from the pharmaceutical industry. Int J Res Market 25:273–281CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Washington State UniversityTri-CitiesUSA

Personalised recommendations